ArriVent BioPharma (AVBP) Stock Chart & Stock Price History → America’s worst nightmare? (From Porter & Company) (Ad) Free AVBP Stock Alerts $17.93 +0.23 (+1.30%) (As of 05/13/2024 ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media ArriVent BioPharma Stock Price Performance5 Day Performance+3.28%1 Month Performance+6.16%3 Month Performance-18.13% Receive AVBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Huge AlertsThis 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!Sign Up for the Live Broadcast here AVBP Stock Chart for Monday, May, 13, 2024 AVBP Chart by TradingView ArriVent BioPharma Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/13/2024$17.70$17.93+1.30%$18.51$16.9747,943 shs$600.48 million05/10/2024$17.99$17.70-1.61%$18.00$17.3927,905 shs$592.84 million05/09/2024$17.36$17.99+3.63%$17.99$17.3630,615 shs$602.56 million05/08/2024$17.25$17.36+0.64%$17.85$16.8240,811 shs$581.46 million05/07/2024$17.24$17.25+0.06%$17.62$17.0241,505 shs$577.77 million05/06/2024$17.23$17.24+0.06%$17.63$16.9325,226 shs$577.37 million Get the Latest News and Ratings for AVBP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. 05/03/2024$16.80$17.23+2.56%$17.51$16.7623,943 shs$577.03 million05/02/2024$16.69$16.80+0.66%$17.39$16.5462,370 shs$562.70 million05/01/2024$16.52$16.69+1.03%$17.42$15.7965,808 shs$558.95 million04/30/2024$16.34$16.52+1.10%$16.96$15.66108,462 shs$553.26 million04/29/2024$15.44$16.34+5.83%$16.64$15.3652,617 shs$547.23 million04/26/2024$15.54$15.44-0.64%$16.47$15.4053,529 shs$517.09 million04/25/2024$15.30$15.54+1.57%$15.88$14.3568,890 shs$520.44 million04/24/2024$15.77$15.30-2.98%$16.08$14.75130,345 shs$512.40 million04/23/2024$15.90$15.77-0.82%$16.29$15.3186,950 shs$528.20 million04/22/2024$15.50$15.90+2.58%$16.65$15.60115,535 shs$532.49 million04/19/2024$15.50$15.50$16.26$15.1734,155 shs$519.10 million04/18/2024$16.04$15.50-3.37%$17.04$14.74629,988 shs$519.10 million04/17/2024$16.80$16.04-4.52%$16.93$15.50194,788 shs$537.18 million04/16/2024$17.00$16.80-1.18%$17.55$16.44258,462 shs$562.63 million04/15/2024$16.89$17.00+0.65%$17.35$16.55311,965 shs$569.33 million04/12/2024$17.67$16.89-4.41%$17.85$16.6797,650 shs$565.65 million04/11/2024$17.29$17.67+2.20%$17.95$17.1071,831 shs$591.77 million04/10/2024$17.33$17.29-0.23%$17.66$16.9196,319 shs$579.04 million04/09/2024$17.49$17.33-0.91%$17.83$17.15132,269 shs$580.45 million04/08/2024$18.45$17.49-5.20%$18.54$17.34137,708 shs$585.74 million04/05/2024$18.30$18.45+0.82%$18.98$18.1241,494 shs$617.89 million04/04/2024$18.12$18.30+0.99%$18.54$17.8577,510 shs$612.94 million04/03/2024$18.00$18.12+0.67%$18.20$17.87122,190 shs$606.84 million04/02/2024$18.31$18.00-1.69%$18.20$17.92138,099 shs$575.28 million04/01/2024$17.86$18.31+2.52%$19.11$17.74357,779 shs$585.19 million03/29/2024$17.86$17.86$18.30$17.73233,160 shs$570.75 million03/28/2024$18.00$17.86-0.78%$18.30$17.73233,160 shs$570.81 million03/27/2024$17.80$18.00+1.12%$18.31$17.50121,847 shs$575.28 million03/26/2024$16.96$17.80+4.95%$18.04$16.91132,790 shs$568.89 million03/25/2024$18.28$16.96-7.22%$18.22$16.90121,475 shs$542.04 million03/22/2024$18.21$18.28+0.38%$18.46$17.8484,716 shs$584.23 million03/21/2024$18.42$18.21-1.14%$18.51$17.58172,738 shs$581.99 million03/20/2024$18.13$18.42+1.60%$18.67$17.67178,129 shs$588.70 million03/19/2024$18.55$18.13-2.26%$18.57$17.65298,818 shs$579.38 millionFree report reveals “two-baggers” for 2024 (Ad)We’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable.Download your free report today!03/18/2024$19.49$18.55-4.82%$19.78$18.14301,289 shs$592.86 million03/15/2024$18.57$19.49+4.95%$20.15$18.281.97 million shs$622.90 million03/14/2024$19.75$18.57-5.97%$19.75$17.69261,998 shs$593.50 million03/13/2024$19.15$19.75+3.13%$19.83$19.02149,831 shs$631.21 million03/12/2024$19.33$19.15-0.93%$19.96$18.75159,785 shs$612.03 million03/11/2024$19.61$19.33-1.43%$20.32$19.10111,746 shs$617.79 million03/08/2024$20.10$19.61-2.44%$20.70$19.6191,477 shs$626.74 million03/07/2024$20.25$20.10-0.74%$20.72$19.65121,599 shs$642.40 million03/06/2024$20.43$20.25-0.88%$21.43$20.11107,710 shs$647.19 million03/05/2024$22.75$20.43-10.20%$22.50$20.43139,563 shs$652.88 million03/04/2024$20.94$22.75+8.64%$22.99$20.57183,082 shs$727.09 million03/01/2024$21.54$20.94-2.79%$22.20$20.60136,934 shs$669.24 million02/29/2024$20.45$21.54+5.33%$22.29$20.34169,140 shs$688.42 million02/28/2024$19.54$20.45+4.66%$21.01$19.12306,712 shs$653.58 million02/27/2024$18.94$19.54+3.17%$20.10$18.61229,685 shs$624.50 million02/26/2024$19.32$18.94-1.97%$19.67$18.63186,345 shs$605.32 million02/23/2024$19.67$19.32-1.78%$20.50$19.18183,099 shs$617.47 million02/22/2024$19.88$19.67-1.06%$20.14$18.37319,678 shs$628.65 million02/21/2024$20.63$19.88-3.64%$21.44$19.66219,872 shs$635.37 million02/20/2024$22.47$20.63-8.19%$22.75$20.31181,203 shs$659.27 million02/19/2024$22.47$22.47$22.51$21.2573,300 shs$718.14 million02/16/2024$22.07$22.47+1.81%$22.51$21.2573,303 shs$718.14 million02/15/2024$21.48$22.07+2.75%$22.15$21.2092,542 shs$705.29 million02/14/2024$21.90$21.48-1.92%$22.20$21.16113,989 shs$686.50 million02/13/2024$21.03$21.90+4.14%$22.05$20.00250,128 shs$699.92 million02/12/2024$21.01$21.03+0.10%$21.94$20.6883,723 shs$672.12 million Related Companies: Aerovate Therapeutics Stock Chart Calliditas Therapeutics AB (publ) Stock Chart Y-mAbs Therapeutics Stock Chart IGM Biosciences Stock Chart Phathom Pharmaceuticals Stock Chart GH Research Stock Chart Stoke Therapeutics Stock Chart Pharming Group Stock Chart ORIC Pharmaceuticals Stock Chart Astria Therapeutics Stock Chart Receive AVBP Stock News and Ratings via EmailSign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:AVBP) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.